Alpha Cognition Drug Patent Portfolio
Alpha Cognition owns 1 orange book drug protected by 4 US patents Given below is the list of Alpha Cognition's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12208167 | Coated tablets for pH-dependent release of benzgalantamine | 26 Feb, 2044 | Active |
| US12208176 | Process for making dry and stable hemostatic compositions | 26 Feb, 2044 | Active |
| US11795176 | Solid forms of Alpha-1062 gluconate | 13 Jan, 2042 | Active |
| US9763953 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | 01 Dec, 2026 | Active |
Latest Legal Activities on Alpha Cognition's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Alpha Cognition.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US9763953 |
| Information Disclosure Statement (IDS) Filed | 26 Aug, 2025 | US9763953 |
| transaction for FDA Determination of Regulatory Review Period | 01 Aug, 2025 | US9763953 |
| Patent eCofC Notification | 01 Apr, 2025 | US12208167 |
| Mail Patent eCofC Notification | 01 Apr, 2025 | US12208167 |
| Recordation of Patent eCertificate of Correction | 01 Apr, 2025 | US12208167 |
| Email Notification | 01 Apr, 2025 | US12208167 |
| Second letter to regulating agency to determine regulatory review period | 26 Mar, 2025 | US9763953 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Mar, 2025 | US9763953 |
| Mail Certificate of Correction Memo | 13 Mar, 2025 | US12208167 |
| Post Issue Communication - Certificate of Correction | 11 Mar, 2025 | US12208167 |
| Certificate of Correction Memo | 11 Mar, 2025 | US12208167 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Mar, 2025 | US9763953 |
| Email Notification | 28 Jan, 2025 | US12208176 |
| Mail Patent eGrant Notification | 28 Jan, 2025 | US12208176 |
Alpha Cognition's Family Patents
Alpha Cognition Drug List
Given below is the complete list of Alpha Cognition's drugs and the patents protecting them.
1. Zunveyl
Zunveyl is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12208167 | Coated tablets for pH-dependent release of benzgalantamine |
26 Feb, 2044
(17 years from now)
| Active |
| US12208176 | Process for making dry and stable hemostatic compositions |
26 Feb, 2044
(17 years from now)
| Active |
| US11795176 | Solid forms of Alpha-1062 gluconate |
13 Jan, 2042
(15 years from now)
| Active |
| US9763953 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
01 Dec, 2026
(8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zunveyl's drug page